Cart
sales@molnova.com
PF-04965842
CAS No. 1622902-68-4
PF-04965842( Abrocitinib | PF 04965842 | PF04965842 )
Catalog No. M12393 CAS No. 1622902-68-4
PF-04965842 (Abrocitinib, PF04965842) is a potent, selective, orally bioavailable JAK1 inhibitor with IC50 of 29 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 67 | In Stock |
|
| 2MG | 38 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 107 | In Stock |
|
| 25MG | 256 | In Stock |
|
| 50MG | 455 | In Stock |
|
| 100MG | 821 | In Stock |
|
| 200MG | 1107 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePF-04965842
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-04965842 (Abrocitinib, PF04965842) is a potent, selective, orally bioavailable JAK1 inhibitor with IC50 of 29 nM.
-
DescriptionPF-04965842 (Abrocitinib, PF04965842) is a potent, selective, orally bioavailable JAK1 inhibitor with IC50 of 29 nM; exhibits good selective inhibition profile for JAK1 versus other JAK family enzymes (IC50=803/>10,000/1250 nM for JAK2/JAK3/TYK2, respectively); demonstrates efficacy in a rat adjuvant-induced arthritis (rAIA) model.Dermatitis Phase 3 Clinical(In Vitro):Abrocitinib (Compound 25) inhibits IFNα-stimulated phosphorylation of STAT3, IFN-stimulated phosphorylation of STAT1 in human whole blood (HWB), as well as pSTAT5 in CD34+ spiked into HWB (JAK2), with IC50s of 189, 163 nM, 7.178 μM, respectively.(In Vivo):Abrocitinib (Compound 25; 5, 15, 50 mg/kg, p.o., daily for 7 days) significantly reduces paw swelling in rat adjuvant-induced arthritis model.
-
In VitroAbrocitinib (Compound 25) inhibits IFNα-stimulated phosphorylation of STAT3, IFN-stimulated phosphorylation of STAT1 in human whole blood (HWB), as well as pSTAT5 in CD34+ spiked into HWB (JAK2), with IC50s of 189, 163 nM, 7.178 μM, respectively.
-
In VivoAbrocitinib (Compound 25; 5, 15, 50 mg/kg, p.o., daily for 7 days) significantly reduces paw swelling in rat adjuvant-induced arthritis model. Animal Model:Female Lewis rats (8?10 weeks old)Dosage:5, 15, 50 mg/kg Administration:P.O. daily for 7 days Result:Obviously reduced paw swelling at all doses.
-
SynonymsAbrocitinib | PF 04965842 | PF04965842
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK
-
Research AreaInflammation/Immunology
-
IndicationDermatitis
Chemical Information
-
CAS Number1622902-68-4
-
Formula Weight323.415
-
Molecular FormulaC14H21N5O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 125 mg/mL 386.51 mM
-
SMILESCCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3
-
Chemical NameN-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
CHZ-868
A potent type II JAK2 inhibitor; inhibits the proliferation of SET2 JAK2 V617F cells.
-
Reticuline
Reticuline, isolated from Litsea cubeba, shows anti-inflammatory effects through JAK2/STAT3 and NF-κB signaling pathways.
-
PF-06651600
PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical
